SG11201500892UA - Anti-poly-n-acetyl glucosamine (pnag) monoclonal antibody and uses thereof for the prevention or treatment of pnag expressing bacterial infection - Google Patents

Anti-poly-n-acetyl glucosamine (pnag) monoclonal antibody and uses thereof for the prevention or treatment of pnag expressing bacterial infection

Info

Publication number
SG11201500892UA
SG11201500892UA SG11201500892UA SG11201500892UA SG11201500892UA SG 11201500892U A SG11201500892U A SG 11201500892UA SG 11201500892U A SG11201500892U A SG 11201500892UA SG 11201500892U A SG11201500892U A SG 11201500892UA SG 11201500892U A SG11201500892U A SG 11201500892UA
Authority
SG
Singapore
Prior art keywords
pnag
poly
prevention
treatment
monoclonal antibody
Prior art date
Application number
SG11201500892UA
Inventor
Astrid Rey
Cathy Cantalloube
Meng Li
Lei Tang
Daniel Vlock
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of SG11201500892UA publication Critical patent/SG11201500892UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
    • G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)
SG11201500892UA 2012-08-24 2013-08-22 Anti-poly-n-acetyl glucosamine (pnag) monoclonal antibody and uses thereof for the prevention or treatment of pnag expressing bacterial infection SG11201500892UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261693001P 2012-08-24 2012-08-24
FR1356743 2013-07-09
PCT/US2013/056124 WO2014031822A1 (en) 2012-08-24 2013-08-22 Anti-poly-n-acetyl glucosamine (pnag) monoclonal antibody and uses thereof for the prevention or treatment of pnag expressing bacterial infection

Publications (1)

Publication Number Publication Date
SG11201500892UA true SG11201500892UA (en) 2015-03-30

Family

ID=50150380

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201500892UA SG11201500892UA (en) 2012-08-24 2013-08-22 Anti-poly-n-acetyl glucosamine (pnag) monoclonal antibody and uses thereof for the prevention or treatment of pnag expressing bacterial infection

Country Status (10)

Country Link
US (1) US20150210755A1 (en)
EP (1) EP2888278A1 (en)
JP (1) JP2015526474A (en)
CN (1) CN104955840A (en)
AU (1) AU2013305705A1 (en)
CA (1) CA2882889A1 (en)
HK (1) HK1211298A1 (en)
MX (1) MX2015002435A (en)
SG (1) SG11201500892UA (en)
WO (1) WO2014031822A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
SI1745075T1 (en) 2004-04-21 2013-07-31 The Brigham And Women's Hospital, Inc. Poly-n-acetyl glucosamine (pnag/dpnag)-binding peptides and methods of use thereof

Also Published As

Publication number Publication date
CN104955840A (en) 2015-09-30
WO2014031822A1 (en) 2014-02-27
JP2015526474A (en) 2015-09-10
MX2015002435A (en) 2015-06-22
AU2013305705A1 (en) 2015-03-12
CA2882889A1 (en) 2014-02-27
EP2888278A1 (en) 2015-07-01
US20150210755A1 (en) 2015-07-30
HK1211298A1 (en) 2016-05-20

Similar Documents

Publication Publication Date Title
IL227193B (en) Plant extracts for the treatment and prevention of infections
HK1207002A1 (en) Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections
EP2558493A4 (en) Antibodies for the treatment of clostridium difficile-associated infection and disease
IL232219B (en) Human or humanized anti-tar-dna-binding protein 43kda antibodies and uses thereof
HK1210022A1 (en) Methods for the treatment of hepatitis b and hepatitis d infections
HK1210018A1 (en) Tailored liposomes for the treatment of bacterial infections
GB201217097D0 (en) Treatment of bacterial infection
EP2652508A4 (en) The use of anti-cxcl13 and anti-cxcr5 antibodies for the treatment or detection of cancer
HRP20160150T1 (en) Treatment of streptococcal infections
HK1248535A1 (en) Treatment or prevention of infection
AP2015008338A0 (en) Compounds for the treatment and prevention of retroviral infections
HK1202539A1 (en) (r) -nifuratel, its use for the treatment of infections and synthesis of (r) and (s) -nifuratel (r)-(r)(s)-
EP2895511A4 (en) The use of antibodies in treating hiv infection and suppressing hiv transmission
HK1212619A1 (en) Method of treatment or prophylaxis of infections of the eye
HK1201181A1 (en) Novel cyclosporin derivatives for the treatment and prevention of viral infections
LT2640728T (en) Novel monensin derivatives for the treatment and prevention of protozoal infections
FI20105970A0 (en) Improved nutritional compensation for the treatment and prevention of cancer
PT2862576T (en) Microorganisms and compositions comprising them for use in the treatment or prevention of mastitis
HK1211298A1 (en) Anti-poly-n-acetyl glucosamine (pnag) monoclonal antibody and uses thereof for the prevention or treatment of pnag expressing bacterial infection n-(pnag) pnag
AU2012902449A0 (en) Novel animal infection treatment and prophylaxis
AU2011902348A0 (en) Novel treatment and prevention of dog viral infections
AU2011902607A0 (en) Animal infection treatment and prophylaxis
EP2670407A4 (en) Treatment of bacterial infections
ZA201309332B (en) Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
AU2012900286A0 (en) "Methods of treatment or prophylaxis"